
SURE Canada study was a multicenter, prospective, observational study investigating once‐weekly (OW) semaglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), in patients with type 2 diabetes (T2D) in routine clinical practice. Adults with T2D and ≥ 1 documented HbA1c value ≤12 weeks before semaglutide initiation were enrolled. Primary endpoint was change from baseline in HbA1c to end of study (EOS; ~30 weeks)...
Like
Save
Share